FDA approves Bayer's Nubeqa with ADT for metastatic hormone-sensitive prostate cancer, cutting death risk by 46%. Read more ...

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...

The company said this morning that the COAST trial of sozinibercept (OPT-302) as a combination therapy with blockbuster wet AMD therapy Regeneron/Bayer's Eylea ... the first treatment for wet ...

The launch ceremony of Bayer E-Town Open Innovation Center is held in Beijing on Monday. [Photo provided to China Daily] Germany-based life sciences giant Bayer unveiled Bayer E-Town Open ...

Recent therapeutic advances have led to modest improvement in outcome for ... An example of a biomarker predictive of treatment response is chromosomal 1p and 19q tumor deletion among anaplastic ...

Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.